Table 5.

Chemotherapy regimens received by patients in the non-cisplatin group

Type of chemotherapy	Number of patients (%) N = 200
Capecitabine + Oxaliplatin/5-FU + Leucovorin + Oxaliplatin/Epirubicin + Oxaliplatin + Capecitabine	34 (17)
5-FU + Irinotecan + Leucovorin/5-FU + Irinotecan + Leucovorin + Cetuximab/Irinotecan + Cetuximab	18 (9)
Doxorubicin + Cyclophophamide/5-FU + Epirubicin + Cyclophophamide/Epirubicin + Cyclophophamide	24 (12)
Paclitaxel/Paclitaxel + Herceptin	22 (11)
Docetaxel/Docetaxel + Herceptin	26 (13)
Adrimacycin + Ifosfamide	8 (4)
Carboplatin + Paclitaxel	34 (17)
CHOP/ABVD (Cyclophosphamide + Adriamycin + Vincristine + Prednisone)/(Adriamycin + Bleomycin + Vinblastine + Dacarbazine)	12 (6)
VAC alternating with IE (Vincristine + Adriamycin + Cyclophosphamide alternating with Ifosfamide + Etoposide)	4 (2)
5-FU + Oxaliplatin + Irinotecan + Leucovorin	8 (4)
Gemcitabine	6 (3)
Carboplatin + Gemcitabine	2 (1)
Others	2 (1)